The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: I was wondering if you could say how many active patients around Xywav currently.
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Just follow-up on last question (inaudible).
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Could you hear me now?
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: I was just (inaudible) anything potentially this year in the guidance and just how you're preparing to launch the indication into the market. So now
that you've had a lot more time to think about the overall opportunity, just give us a better sense of how you're going to be going after that once
it's (inaudible)
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: No, it was idiopathic hypersomnia. I don't know why -- I'm sorry for the connection, bad connection. Yes. Just -- yes, do you have more time to think
about it, the overall opportunity. And if it's in the guidance for this year, if there's anything baked into the latter part of this year once it's approved.
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: I hadn't thought to ask Jed a question, but since he's got the mic, maybe you could offer any thoughts you have on cannabinoids and sleep. I'm
guessing you have some thoughts there. But my other question was for Renee. When you closed the GW deal, do you provide updated guidance
right on the back of that or the next scheduled quarterly conference call, maybe you could just set the stage first on what and how you will guide.
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Congratulations on another good quarter. Maybe just changing gears a little bit here and focusing on Zepzelca. Another good quarter there. Can
you provide some color in terms of how much pent-up demand are we still seeing in third and fourth-line versus pure second line? And I know
you mentioned that both platinum incentive and platinum resistent are growing usage. Any way to parse that out a bit more just in terms of the
uptake between sensitive and resistant?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 23, 2021 / 9:30PM, JAZZ.OQ - Q4 2020 Jazz Pharmaceuticals PLC Earnings Call
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Okay. And are we still seeing usage from certain fourth line patients as we saw last quarter?
| 
